Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the beneficial effect of heart rate reduction of oral ivabradine
in patients presenting with non ST-segment elevation myocardial infarction (NSTEMI) during
acute stage post percutaneous coronary intervention versus conventional treatment.
Materials and methods: A total of 100 patients admitted to the emergency department, National
Heart Institute, Cairo, Egypt were randomized into two groups as follows: Group A: 50
patients with NSTEMI treated with ivabradine (5mg twice daily) in addition to the
conventional treatment; Group B: 50 patients with NSTEMI treated with the conventional
treatment only. Demographic data, detailed history, clinical examination, chest pain onset,
blood pressure, heart rate (HR), temperature and respiratory rate, electrocardiogram (ECG) as
well as echocardiography and laboratory investigations were recorded. Patients were monitored
for a period of 3-5 days (acute stage).